NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet...(gh eight compared with patients who rece...),Health

Date:1/12/2009

gh eight, compared with patients who received the control patch. Reduction in pain during Weeks two through twelve was also significantly greater in patients treated with Qutenza. Qutenza was generally well tolerated. The most common adverse effects were related to local, application site reactions and treatment-associated pain.

Anthony DiTonno, President and CEO, commented, "Current PHN treatment options have limitations that we believe present an opportunity for Qutenza to address. In addition to the potential for a long duration of effect, Qutenza acts locally, at the pain site, as opposed to through the central nervous system, and has the potential to manage pain resulting from PHN without causing some of the common side effects associated with currently available systemic treatment options. With both our NDA and MAA currently under review, we look forward to regulatory decisions on these applications and the potential for subsequent commercial launches of Qutenza in both the United States and European Union."

The first author of the publication, Miroslav Backonja M.D., Professor of Neurology, Anesthesiology and Rehabilitation Medicine at the University of Wisconsin School of Medicine, stated, "The results from the Phase 3 C116 study of Qutenza in patients with PHN showed that a single 60-minute application of Qutenza has the potential to provide targeted pain management for up to 12 weeks. I am very glad that Qutenza has the potential upon approval to offer our patients a significant improvement to the current treatment options for PHN."

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN
'/>"/>

SOURCE NeurogesX, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
2. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
3. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
4. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
5. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
6. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
7. Pulmo BioTech Inc. Announces Dual Listing on Frankfurt Borse
8. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
9. Anesiva Announces FDA Approval of Supplemental New Drug Application to Expand Zingo(TM) Indication
10. ProUroCare Medical Inc. Announces Pricing of Equity Offering
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function